Integra LifeSciences Announces Acquisition of Neuron Therapeutics' Patent Estate
"The acquisition of the Neuron Therapeutics IP estate broadens our technology base in the management of neurotrauma, one of our key markets," said Simon Archibald, Ph.D., Integra's vice president of clinical affairs. "This new technology has the potential to give physicians a direct physical intervention to treat the injured tissues of the brain and reduce the secondary events to neurotrama that account for the majority of neuronal death and functional deficits seen in these patients. The core of Neuron Therapeutics approach is a system that bathes the brain in a cooled, hyper-oxygenated fluid that provides metabolic support and removes toxins from the injured tissues."
Bruce Shook, the former chief executive officer of Neuron Therapeutics, remarked, "I am pleased that Integra has acquired Neuron Therapeutics' patent estate. Integra has a strong reputation for bringing innovative medical devices to the neurosciences marketplace. I am very proud of the technology that we've developed and look forward to its commercialization."
Integra LifeSciences Holdings Corporation is a diversified medical technology company that develops, manufactures, and markets medical devices for use in a variety of applications. The primary applications for our products are neuro-trauma and neurosurgery, plastic and reconstructive surgery, and soft tissue repair. Integra is a leader in applying the principles of biotechnology to medical devices that improve patients' quality of life. The Company has its corporate headquarters in Plainsboro, New Jersey, with manufacturing and research facilities located throughout the world. The Company has approximately 860 permanent employees. Please visit the Company's Website at (http://www.Integra-LS.com).
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning expectations for future development of products based on the acquired intellectual property and the clinical applications of such products. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, Integra's development efforts and its ability to obtain regulatory approval to market future products based on the acquired intellectual property could affect the success and timing of commercialization of the acquired intellectual property and the results of clinical trials involving products based on the acquired intellectual property could affect the use of such products in desired clinical applications. In addition, the economic, competitive, governmental, technological and other factors identified under the heading "Risk Factors" included in the Business section of Integra's Annual Report on Form 10-K for the year ended December 31, 2002 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
Source: Integra LifeSciences Holdings Corporation
Contacts:
Integra LifeSciences Holdings Corporation
John B. Henneman, III
Executive Vice President
Chief Administrative Officer
(609) 936-2481
jhenneman@integra-ls.com
John Bostjancic
Senior Director of Finance
(609) 936-2239
jbostjancic@integra-ls.com